Development of Monoclonal Antibody-mediated Interventions to Combat Malaria
$300,000N43FY2022AINIH
Antagen Pharmaceuticals, Inc., Boston MA
Investigators
Abstract
To support proof of concept studies for the development of a monoclonal antibody to combat malaria.
View original record on NIH RePORTER →